Skip to content

Somapacitan

Published: July 26, 2026Updated: July 26, 2026

Somapacitan is a long-acting recombinant growth hormone (GH) analog that binds to growth hormone receptors on target cells, triggering intracellular signaling pathways that stimulate the production of insulin-like growth factor-1 (IGF-1). It is designed for once-weekly administration and is used to treat growth hormone deficiency in both adults and children, providing a more convenient alternative to daily growth hormone injections.

Quick summary

A once-weekly growth hormone replacement therapy for growth hormone deficiency in adults and children.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

ATC
H01AC07
RxNorm
2557373
Generic
Somapacitan
Class
atc-h01
Brands
Sogroya
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Treatment of growth hormone deficiency in adults and pediatric patients. It provides growth hormone replacement therapy with less frequent dosing than traditional daily growth hormone products.

Somapacitan binds to dimeric growth hormone receptors on target cell membranes, activating intracellular signal transduction pathways. The resulting pharmacodynamic effects are primarily mediated through insulin-like growth factor-1 (IGF-1) production, which promotes growth, metabolic regulation, and other growth hormone-dependent physiological processes.

Growth hormone therapy requires careful monitoring of IGF-1 levels, metabolic parameters, and potential side effects. Treatment should be supervised by specialists experienced in managing growth hormone disorders. Not recommended for patients with active malignancy, severe obesity, or acute critical illness.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy